



August 23, 2021

BSE Limited Code: 532321

1st Floor, P J Towers, Dalal Street, <u>Mumbai-400001</u>

National Stock Exchange of India Limited Code: Cadilahc

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated August 23, 2021 titled "Zydus Cadila gets 180-day exclusivity for Tofacitinib extended-release 22 mg tablets".

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Zydus Cadila gets 180-day exclusivity for Tofacitinib extendedrelease 22 mg tablets, announces final approval from USFDA

August 23, 2021, Ahmedabad, India

Zydus Cadila has received final approval from the USFDA to market Tofacitinib extended-release tablets, 11 mg and 22 mg in the United States (ANDA-214264 and US RLD: XELJANZ XR). Zydus was the first ANDA filer on Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength.

Tofacitinib extended-release tablets had annual sales of approximately \$2,082 million in the United States for the year ending June 2021 according to IQVIA data. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics, and vaccines. The group employs 25,000 people worldwide and is dedicated to creating healthier communities globally. For more information, please visit www.zyduscadila.com/

CIN: L24230GJ1995PLC025878